samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > a conversation about systemic sclerosis
PUBLICATIONS
European Biopharmaceutical Review

A Conversation About Systemic Sclerosis

EBR:With systemic sclerosis (SSc), commonly known as scleroderma, and estimated to range from 50 to 300 cases per 1 million people, many might not know the specifics of the disease. Can you give an overview of its symptoms, causes, and effects?

Dr Alexandre Akoulitchev: SSc is a rare autoimmune disease. What distinguishes it from others is that it has the highest case fatality of any rheumatic disease, largely from heart or renal failure, in the advanced stage. The survival rate is only 55% at 10 years post-diagnosis. The disease starts with the skin and connective tissues, marked by the overproduction of collagen, and later can affect blood vessels, muscles, hearing, digestive system, lungs (pulmonary fibrosis), and kidneys. Disease incidence is estimated at 18.7 cases per million per year. In the US, over 6,000 new cases are diagnosed every year. There are several classification criteria for SSc: from 2013ACR/EULAR scoring, to serological subtyping (limited and diffuse), to classification based on gene expression (limited, inflammatory, fibroproliferative).

Ultimately, today, the exact causes of SSc, linked to collagen overproduction, remain unknown. As a multifactorial disease with defined clinical outcomes, its patient subtypes and pathogenic pathways involved remain highly heterogeneous. This poses serious challenges to clinical prognosis and trial designs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Alexandre Akoulitchev, MA, FRSM, is Chief Scientific Officer at Oxford BioDynamics, a leader in analysing 3D genomics using its liquid biopsy platform, EpiSwitch. Alexandre studied Mathematics, Physics, Chemistry, Biochemistry, and Biophysics at the Moscow Institute of Physics and Technology, Russia. In 1989, he was selected by the George Soros Foundation for the Oxford Scholarship. Alexandre obtained his PhD in cell biology from UCL, UK, and spent six years at the Robert Wood Johnson Medical School-University of Medicine and Dentistry of New Jersey, US, as a research assistant. Upon his return to England, he established his research laboratory at the Sir William Dunn School of Pathology, University of Oxford, UK. He was a University Academic Fellow (Research Council, UK) and a Senior Fellow of Exeter College, UK, sponsored by Cancer Research UK, the Wellcome Trust, and The Medical Research Council. Alexandre is a Fellow of the Royal Society of Medicine.

Dr Ewan Hunter, BSc, Chief Data Officer at Oxford BioDynamics obtained his first degree in Biochemistry from Edinburgh University, UK, after which he went to Guy’s and St Thomas’s Medical School, King’s College London, UK, to complete his PhD in Statistical Molecular Neurobiology. Since completing his degrees, Ewan has worked for several biotechnology vendor companies, including Silicon Genetics, Agilent, and Thomson Reuters in business and technical roles. Ewan joined Oxford BioDynamics in 2012, there he has driven the early biomarker direction, developed statistical and data pipelines, and now he is responsible for leveraging the value of EpiSwitch chromosome conformation data with customers and partners.
spacer
Dr Alexandre Akoulitchev
spacer
spacer
spacer
Dr Ewan Hunter
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New laboratory and regulatory services for biotech customers

USA/Germany, September 21, 2020. Gerresheimer adds essential laboratory and regulatory services to its broad portfolio of products, solutions and services for biotech companies. Specialized laboratory technicians and an experienced team of further specialists offer these services in the two innovation and technology centers in Bünde (Germany) and Vineland (New Jersey/USA). Gx Biological Solutions offers full service for biotech companies regarding product development of primary packaging and drug delivery solutions, material and functional testing as well as comprehensive regulatory support. The partnership with Gerresheimer shortens the time to market for pharmaceutical companies, minimizes risks and saves resources.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement